文献速递神经核医学肿瘤 PET/CT

44例胶质瘤动态18F-FET PET/CT参数、组织学与甲基化谱整合分析

Integrated analysis of dynamic FET PET/CT parameters, histology, and methylation profiling of 44 gliomas.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2018-05-07

对44例初诊未治疗胶质瘤患者(WHO II级10例、III级13例、胶质母细胞瘤21例)行动态18F-FET PET/CT,并与组织学诊断及Illumina 850K甲基化阵列的表观遗传分析进行整合。表观遗传分型使6例II/III级胶质瘤重新归类为胶质母细胞瘤,基于甲基化分型后高、低级别胶质瘤典型时间-活性曲线的重叠明显减少;基于甲基化诊断时胶质母细胞瘤与II/III级胶质瘤间达峰时间差异更大,多变量分析显示基于甲基化诊断的诊断准确率略高。结论认为动态18F-FET PET作为具有生物学与临床相关性的影像方法在分子胶质瘤诊断背景下得到确认。

要点

  • 表观遗传分型使6例II/III级胶质瘤重新归类为胶质母细胞瘤。
  • 基于甲基化分型后高、低级别胶质瘤典型时间-活性曲线的重叠明显减少。
  • 基于甲基化诊断时胶质母细胞瘤与II/III级胶质瘤间达峰时间差异更大,多变量分析显示基于甲基化诊断的诊断准确率略高。

核心结论

  • 动态18F-FET PET作为具有生物学与临床相关性的影像方法在分子胶质瘤诊断背景下得到确认。

研究设计与样本

  • 对44例初诊未治疗胶质瘤患者行动态18F-FET PET,其中WHO II级10例、III级13例、胶质母细胞瘤21例,均在PET后接受立体定向活检或肿瘤切除。
  • 对组织样本行组织学分析,并用Illumina 850K甲基化阵列对DNA行表观遗传分析。
  • 将时间-活性曲线、经健康组织背景校正的标准化摄取值(SUVmax/BG)、达峰时间及动力学建模参数与组织学诊断和表观遗传特征进行相关分析,并行多变量分析评估诊断准确率。

主要发现

  • 表观遗传分型导致明显肿瘤重新分类,6例II/III级胶质瘤被重新归类为胶质母细胞瘤。
  • 基于甲基化谱对肿瘤聚类后,高、低级别胶质瘤典型时间-活性曲线的重叠明显减少。
  • 按组织学诊断和按甲基化诊断,胶质母细胞瘤的SUVmax/BG值均高于低级别胶质瘤。
  • 基于甲基化诊断时胶质母细胞瘤与II/III级胶质瘤之间的达峰时间差异大于基于组织学诊断时。
  • 动力学建模显示,在组织学和甲基化诊断的胶质母细胞瘤与II/III级胶质瘤中,相对K1和分形维数值在组织学诊断与甲基化分析诊断之间存在显著差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Dynamic 18F-FET PET/CT is a powerful tool for the diagnosis of gliomas.18F-FET PET time-activity curves (TAC) allow differentiation between histological low-grade gliomas (LGG) and high-grade gliomas (HGG). Molecular methods such as epigenetic profiling are of rising importance for glioma grading and subclassification. Here, we analysed dynamic 18F-FET PET data, and the histological and epigenetic features of 44 gliomas. METHODS: Dynamic 18F-FET PET was performed in 44 patients with newly diagnosed, untreated glioma: 10 WHO grade II glioma, 13 WHO grade III glioma and 21 glioblastoma (GBM). All patients underwent stereotactic biopsy or tumour resection after 18F-FET PET imaging. As well as histological analysis of tissue samples, DNA was subjected to epigenetic analysis using the Illumina 850 K methylation array. TACs, standardized uptake values corrected for background uptake in healthy tissue (SUVmax/BG), time to peak (TTP) and kinetic modelling parameters were correlated with histological diagnoses and with epigenetic signatures. Multivariate analyses were performed to evaluate the diagnostic accuracy of 18F-FET PET in relation to the tumour groups identified by histological and methylation-based analysis. RESULTS: Epigenetic profiling led to substantial tumour reclassification, with six grade II/III gliomas reclassified as GBM. Overlap of HGG-typical TACs and LGG-typical TACs was dramatically reduced when tumours were clustered on the basis of their methylation profile. SUVmax/BG values of GBM were higher than those of LGGs following both histological diagnosis and methylation-based diagnosis. The differences in TTP between GBMs and grade II/III gliomas were greater following methylation-based diagnosis than following histological diagnosis. Kinetic modeling showed that relative K1 and fractal dimension (FD) values significantly differed in histology- and methylation-based GBM and grade II/III glioma between those diagnosed histologically and those diagnosed by methylation analysis. Multivariate analysis revealed slightly greater diagnostic accuracy with methylation-based diagnosis. IDH-mutant gliomas and GBM subgroups tended to differ in their 18F-FET PET kinetics. CONCLUSION: The status of dynamic 18F-FET PET as a biologically and clinically relevant imaging modality is confirmed in the context of molecular glioma diagnosis.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Röhrich M, Huang K, Schrimpf D, et al. Integrated analysis of dynamic FET PET/CT parameters, histology, and methylation profiling of 44 gliomas. Eur J Nucl Med Mol Imaging. 2018. PMID: 29732524. doi:10.1007/s00259-018-4009-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。